InNexus Biotechnology Inc. Announces Appointment of J. Donald Capra, MD, Chairman of Scientific Advisory Board

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology, Inc. (TSX VENTURE:IXS) (OTCBB:IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation (OMRF), has been appointed Chairman to InNexus’ newly formed Scientific Advisory Board.

MORE ON THIS TOPIC